drugset / Trial / NCT03098550

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550

Phase 1/2 Completed 105 enrolled Bristol-Myers Squibb Janssen Biotech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

Timeline

Start
2017-06-15
Primary completion
2020-07-06
Completion
2020-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab Monoclonal antibody
Subject Nivolumab Monoclonal antibody